

SUPPLEMENTARY INFORMATION

PDX1^{LOW} MAFA^{LOW} β -cells contribute to islet function and insulin release

Daniela Nasteska¹⁻³, Nicholas H.F. Fine¹⁻³, Fiona B. Ashford¹⁻³, Federica Cuzzo¹⁻³, Katrina Vilorio¹⁻³, Gabrielle Smith^{1,3}, Aisha Dahir^{1,3}, Peter W.J. Dawson^{4,5}, Yu-Chiang Lai^{1,4,5}, Aimée Bastidas-Ponce⁶⁻⁹, Mostafa Bakhti⁶⁻⁸, Guy A. Rutter^{10,11}, Remi Fiancette¹², Rita Nano^{13,14}, Lorenzo Piemonti^{13,14}, Heiko Lickert⁶⁻⁹, Qiao Zhou¹⁵, Ildem Akerman^{1,3}, David J. Hodson^{1-3*}

¹Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK

²Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK.

³Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK

⁴School of Sport, Exercise and Rehabilitation Science, University of Birmingham, UK

⁵MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Birmingham, Edgbaston, UK

⁶Institute of Diabetes and Regeneration Research, Helmholtz Zentrum München, D-85764 Neuherberg, Germany

⁷German Center for Diabetes Research (DZD), D-85764 Neuherberg, Germany

⁸Institute of Stem Cell Research, Helmholtz Zentrum München, D-85764 Neuherberg, Germany

⁹Technical University of Munich, School of Medicine, Munich, Germany

¹⁰Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology, and Metabolism, Department of Metabolism, Reproduction, and Digestion, Imperial College London, London, UK

¹¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

¹²Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, B15 2TT, Birmingham, UK


¹³San Raffaele Diabetes Research Institute, IRCCS Ospedale San Raffaele, Italy

¹⁴Vita-Salute San Raffaele University, Milan, Italy

¹⁵Division of Regenerative Medicine, Department of Medicine, Weill Cornell Medical College, New York, USA

*Corresponding author: David J. Hodson, d.hodson@bham.ac.uk

42 **SUPPLEMENTARY FIGURES**




43

44 **Supplementary Figure 1: PDX1 fluorescence intensity distribution plots.** PDX1
45 fluorescence intensity distribution plots shown by individual replicate (n = 6).

46

47




48

49 **Supplementary Figure 2: Raw data and normalization controls for mouse B-MAT**
 50 **islets, NEUROG3 expression and overexpression strength.** **a, b** Non-normalized PDX1
 51 **(a)** and MAFA **(b)** fluorescence intensity-probability distribution showing a decrease in the
 52 proportion of cells occupying the bottom 15 percentile for PDX1 and MAFA expression in B-
 53 MAT versus B-NORM islets (n = 6 islets/3 animals; two-way ANOVA, Bonferroni's multiple
 54 comparison) (PDX1: F = 13.38, DF = 30) (MAFA: F = 3.98, DF = 32). **c**, As for **a**, but wider
 55 bins showing no changes in the proportion of cells occupying the higher fluorescence
 56 intensity ranges in B-MAT versus B-NORM islets (n = 6 islets/3 animals; two-way ANOVA,
 57 Bonferroni's multiple comparison)) (F = 43.25, DF = 3). **d** DAPI nuclear staining intensity
 58 distribution is similar in normal (β -cell normal; B-NORM) and Ad-M3C-transduced (β -cell

59 mature; B-MAT) islets (n = 6 islets/3 animals; two-way ANOVA). **e** Loss of immature β -cells
60 is still evident in B-MAT islets following normalization of PDX1 expression levels versus
61 DAPI for each cell analyzed (n = 6 islets/3 animals; two-way ANOVA) (F = 4.9, DF = 30). **f**
62 As for **e**, but taking into account only cells that are positive for both insulin (INS) and PDX1
63 (n = 6 islets/3 animals; two-way ANOVA) (F = 4.1, DF = 20). **g** NEUROG3 cannot be
64 detected in normal B-NORM islets using specific antiserum, but is faintly present in B-MAT
65 islets (scale bar = 85 μ m). **h** Whole-islet PDX1 fluorescence intensity is only slightly
66 increased in B-MAT versus B-NORM islets (n = 7 islets/3 animals; unpaired t-test). **i** Western
67 blot showing PDX1 and GAPDH expression (run in parallel on separate blots) in B-NORM
68 and B-MAT islets (n = 9 animals, labelled 1 through 9; samples 1 -6 and 7-9 were run on
69 separate gels processed in parallel). A slight shift in the PDX1 band in B-MAT islets is
70 apparent due to the presence of exogenous PDX1. **j** Densitometric quantification of the blots
71 shown in (i) (n = 8 animals, labelled 1-5 and 7-9). Note that B-NORM 6 and B-MAT 6 were
72 omitted from analysis due to poor abundance (i.e. GAPDH was undetectable). Bar graphs
73 show the mean \pm SEM. Box-and-whiskers plot shows median and min-max. All tests are
74 two-sided where relevant.

75




76

77


78 **Supplementary Figure 3: Overexpression localization and time course studies for Ad-**
 79 **M3C.** **a** mCherry expression and thus Ad-M3C viral transduction is significantly higher in
 80 BFP^{LOW} cells (i.e. immature) (n = 48 cells from 7 islets) (unpaired t-test). **b** Representative
 81 images showing mCherry expression in Pdx1-BFP islets 48 hours following infection with
 82 Ad-M3C. White arrows show BFP/PDX1^{HIGH} cells with low mCherry levels, whereas blue
 83 arrows show BFP/PDX1^{LOW} cells with high mCherry levels (scale bar = 26.5 μm). **c-e** The
 84 proportion of β-cells occupying the bottom 15 percentile for PDX1 expression (PDX1^{LOW}) is
 85 reduced in islets transduced with Ad-M3C at 24 hrs post-infection (**c**), and this change is
 86 sustained at 48 hrs (**d**) and 120 hrs (**e**) post-infection (n = 6 islets/3 animals; two-way
 87 ANOVA, Bonferroni's multiple correction) (24 hrs: F = 3.01, DF = 20) (48 hrs: F = 2.24, DF =
 88 20) (120 hrs: F = 4.9, DF = 20). Note that the same 12 hrs (control) PDX1 fluorescence
 89 intensity distribution is shown in all graphs to allow cross-comparison (the experiments were
 90 performed in parallel). **f** Representative images showing PDX1 staining at 12-120 hrs post-
 91 infection (scale bar = 25 μm). **g** An increase in PDX1 fluorescence is apparent after 48 hrs,
 92 as overexpression continues to increase in the targeted cells (n = 9 islets/3 animals; one-

93 way ANOVA, Sidak's multiple correction) ($F = 20.83$, $DF = 3$). Bar graphs show the mean \pm
94 SEM. Violin plot shows median and interquartile range. Box-and-whiskers plot shows
95 median and min-max. All tests are two-sided where relevant.



96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108

Supplementary Figure 4: Overexpression is largely confined to β -cells and ER stress markers are not upregulated. **a** Expression levels of *Arx*, *Pax6* and *Nkx6-1* are not significantly altered in B-MAT islets (n = 4 animals; paired t-test). **b** No difference in the proportion of PDX1⁺GCG⁺ cells was detected in B-NORM compared to B-MAT islets (scale bar = 120 μ m). **c** Imaging of live Ins1Cre;R26^{mT/mG} reporter islets was used to preserve mCherry expression for assessment of localization. No mCherry expression was detected in non- β -cells (tdTomato; grey) at the viral titres used here (n = 17 islets/2 animals) (scale bar = 25 μ m). **d** Expression of the ER stress/UPR markers *Xbp1*, *Hspa5* and *Ddit3* is not significantly altered in B-MAT islets (n = 4 animals; paired t-test). Bar graphs show the mean \pm SEM. All tests are two-sided where relevant. ER-endoplasmic reticulum; UPR-unfolded protein response.




109

110 **Supplementary Figure 5: Ca^{2+} recordings shown by individual preparation, raw insulin**
 111 **secretion data and fold-change insulin release. a, b** Summary bar graphs showing
 112 amplitude of Ca^{2+} responses to glucose (a) or KCl (b) for each separate islet
 113 isolation/preparation, measured using Fluo8 (n = 34 islets/4 preparations/4-5 animals). c, d
 114 Summary bar graphs showing amplitude of Ca^{2+} responses to glucose (c) or KCl (d)
 115 for each separate islet isolation/preparation, measured using Fura2 (n = 33 islets/4 preparations/4
 116 animals). e Uncorrected basal and glucose-stimulated insulin secretion in B-NORM and B-
 117 MAT islets (n = 8 replicates/4 animals). f As for e, but raw Exendin-4-stimulated insulin
 118 secretion (n = 8 replicates/4 animals). g As for e and f, but fold-change glucose- and
 119 Exendin-4-stimulated insulin secretion in B-NORM and B-MAT islets (n = 8 replicates/4
 120 animals; paired t-test). Note that all samples were run together with the same low glucose
 121 control, but due to the relative magnitude, Exendin-4 responses are displayed separately

122 with the same high glucose state (G3, 3 mM glucose; G16.7, 16.7 mM glucose; Ex4, 20 nM
123 Exendin-4). Bar graphs show the mean \pm SEM. All tests are two-sided where relevant.

124



125

126

127 **Supplementary Figure 6: Normalization controls for B-hMAT islets, and insulin**

128 **receptor antagonist experiments.** **a** DAPI nuclear staining intensity distribution is similar

129 in normal (β -cell normal; B-hNORM) and Ad-M3C-transduced (β -cell mature; B-hMAT)

130 human islets ($n = 14$ islets/4 donors; two-way ANOVA). **b** Loss of immature PDX^{LOW} β -cells

131 is still evident in B-hMAT islets following normalization of PDX1 expression levels versus

132 DAPI for each cell analyzed ($n = 13$ islets/4 donors; two-way ANOVA, Bonferroni's multiple

133 comparison) ($F = 2.32$, $DF = 34$). **c** As for **b**, but taking into account only cells that are

134 positive for both insulin (INS) and PDX1 ($n = 8$ islets; two-way ANOVA, Bonferroni's multiple

135 comparison) ($F = 6.15$, $DF = 20$). **d**, **e** Treatment with the insulin receptor antagonist, S961

136 50 nM, increases the proportion of immature PDX1^{LOW} β -cells in wild-type islets versus


137 vehicle (Veh)-treated controls, as shown by frequency distribution (**d**) ($F = 3.97$, $DF = 20$)

138 and representative images (**e**) (scale bar = 25 μ m) ($n = 8$ islets/3 animals; two-way ANOVA,

139 Bonferroni's multiple comparison). Box-and-whiskers plot shows median and min-max. All

139 tests are two-sided where relevant.


140



141

142 **Supplementary Figure 7: Gene expression analyses in D-NORM and D-MAT islets.**
 143 mRNA levels for *Cacna1d*, *Cacna1c*, *Cacnb2*, *Glp1r*, *Gjd2*, *Gck*, *Ins1* and *Ins2* in D-NORM
 144 versus D-MAT chemogenetic islets (n = 6 animals; paired t-test). Bar graphs show paired
 145 observations (before and after). All tests are two-sided where relevant.

146



147

148 **Supplementary Figure 8: Full blot scans corresponding to Supplementary Figure 2i.**

149

150 **SUPPLEMENTARY TABLES**

Unique Identifier	Age group (years)	Gender	BMI (kg/m ²)	Glycemia (mmol/L)* HbA1C (%)	History of diabetes **	Islet purity (%)	Islet culture duration (h)	Country of origin
HP1267	50-55	♂	26.5	6.4 mmol/L	No	90	16	Italy
HP1300	20-25	♂	23.5	5.6 mmol/L	No	70	18	Italy
HP1301	60-65	♀	29	11.6 mmol/L	No	80	14	Italy
HP1306	45-50	♂	27.7	6.8 mmol/L	No	80	18	Italy
HP1319	60-65	♂	23.1	5.2 mmol/L	No	90	42	Italy
HP1325	60-65	♀	23.9	6.1 mmol/L	No	60	19	Italy
HP1331	60-65	♀	19.5	7.1 mmol/L	No	90	16	Italy
HP1332	60-65	♀	29.3	6.1 mmol/L	No	90	14	Italy
HP1356	50-55	♀	19.3	7.1 mmol/L	No	80	16	Italy
HP1365	60-65	♀	27.7	9.3 mmol/L	No	70	65	Italy
HP1373	65-70	♀	21.5	7.1 mmol/L	No	65	18	Italy
R277	45-50	♂	33.7	5.6%	No	75	114	Canada
R278	55-60	♂	27.6	5.7%	No	80	17	Canada
R292	45-50	♂	27.6	5.6%	No	90	17	Canada
R330	35-40	♀	24.2	5.1 %	No	85	33	Canada
R340	35-40	♂	23.3	5.3%	No	95	16	Canada
R341	40-45	♂	30	n/a	No	95	34	Canada
R344	55-60	♂	27.8	5.5%	No	95	42	Canada

151

152 **Supplementary Table 1:** Human islet donor characteristics. *: glycemia values during
 153 Intensive Care Unit stay **: not diagnosed ante-mortem; ♂-male; ♀-female; n/a-not
 154 available; ages are reported as a range in line with the journal indirect identifier policy.

155

Primers		
SYBR Green primers		
<i>β-actin</i>	Sigma	For: CGAGTCGCGTCCACCC Rev: CATCCATGGCGAACTGGTG
<i>Pdx1-native</i>	Sigma	For: ACTTAACCTAGGCGTCGCACAAGA Rev: GGCATCAGAAGCAGCCTCAAAGTT
<i>Pdx1-viral</i>	Sigma	For: TGCCTTCGGGCCTTAGCGT Rev: CCGGGATTCTCCTCCACGT
<i>MafA-native</i>	Sigma	For: CGGGAACGGTGATTGCTTAG Rev: GGAGGTTGGGACGCAGAA
<i>MafA-viral</i>	Sigma	For: TTCCCTCGGGAGCCCTCG Rev: TCTCAACATCTCCAGCCAA
<i>Neurog3-native</i>	Sigma	For: AGGTGATCTGCCTTCTTCTGCACT Rev: ACCGTCCCTGCAACTCACACTTTA
<i>Neurog3-viral</i>	Sigma	For: GCTCCCATCCTATCTGC Rev: TCTTCAACATCTCCTGCTT
<i>Gck</i>	Sigma	For: AGCTGCACCCGAGCTTCA Rev: GATTCGCGAGTTGGGTGTCA
<i>Arx</i>	Sigma	For: TTCCAGAAGACGCACTACCC Rev: TCTGTCAGGTCCAGCCTCAT'
<i>Pax6</i>	Sigma	For: CAGTGTCTACCAGCCAATCC Rev: GCACTGTACGTGTTGGTGAG
<i>Nkx 61</i>	Sigma	For: GCCTGTACCCCCATCAAG Rev: GTGGGTCTGGTGTGTTTTCTCTT
<i>Cacna1c</i>	Sigma	For: CCAACCTCATCCTCTTCTTCA Rev: ACATAGTCTGCATTGCCTAGGAT
<i>Cacna1d</i>	Sigma	For: GAAGCTGCTTGACCAAGTTGT Rev: AACTTCCCACGGTTACCTC
<i>Cacnb2</i>	Sigma	For: GCAGGAGAGCCAGATGGA Rev: TCCTGGCTCCTTTCCATAG
<i>Rfx6</i>	Sigma	For: TGCCAGTGCATACTCGACAAT Rev: AACAGGATTTTCAAGCAGGGG
<i>Xbp1</i>	Sigma	For: AGCAGCAAGTGGTGGATTTG Rev: GAGTTTTCTCCCGTAAAAGCTGA
<i>Hspa5</i>	Sigma	For: ACTTGGGGACCACCTATTCTT Rev: GTTGCCCTGATCGTTGGCTA
<i>Ddit3</i>	Sigma	For: CTGGAAGCCTGGTATGAGGAT Rev: CAGGGTCAAGAGTAGTGAAGGT
<i>Glp1r</i>	Sigma	For: GGGTCTCTGGCTACATAAGGACAAC Rev: AAGGATGGCTGAAGCGATGAC
<i>Adcy8</i>	Sigma	For: TTGGGCTTCTACACCTTGACT Rev: CGGTAGCTGTATCCTCCATTGAG
<i>Gjd2</i>	Sigma	For: GATTGGGAGGATCCTGTTGAC Rev: AGGGCTAGGAAGACAGTAGAG
<i>Ins1</i>	Sigma	For: GTCGGTGGGCATCCAGTAA Rev: AATGACCTGCTTGCTGATGGT
<i>Ins2</i>	Sigma	For: GAAGTGGAGGACCCACAAGT Rev: GATCTACAATGCCACGCTTC
<i>Cox6a2</i>	Sigma	For: GCCCAGCAAGATTCTGTGATG Rev: TCTGGATGTGCGGTAAGGCAT
<i>G6pc2</i>	Sigma	For: ACTCCACAGAAAGGACCAGG Rev: GTCATGGTAACAGCTGCCCT
<i>Ascl1</i>	Sigma	For: TCGTTGGCGAGAAACACTAA Rev: AGGAACAAGAGCTGCTGGAC
<i>Ero1LB</i>	Sigma	For: TGCTGTCAATGTCACATAAGC Rev: AACTGCTTGTACCCTGAGC
<i>Pkib</i>	Sigma	For: CTGCTCCCTTAACTGCTGGAT

		Rev: GATTGTGGAAAAGCGTGTGGT
<i>Rgs4</i>	Sigma	For: GAGTGCAAAGGACATGAAACATC Rev: TTTTCCAACGATTCAGCCCAT
<i>Ucn3</i>	Sigma	For: AAGCCTCTCCACAAGTTCTA Rev: GAGGTGCGTTTGGTTGTCATC
<i>Stx1a</i>	Sigma	For: AAGATTGCCGAAAACGTGGAG Rev: TGCTCAATGCTCTTTAGCTTGG
<i>Snap25</i>	Sigma	For: CAACTGGAACGCATTGAGGAA Rev: GGCCACTACTCCATCCTGATTAT
<i>Vamp2</i>	Sigma	For: GCTGGATGACCGTGCAGAT Rev: GATGGCGCAGATCACTCCC
<i>PPIA</i>	Sigma	For: AAGACTGAGTGGTTGGATGG Rev: ATGGTGATCTTCTTGCTGGT
<i>GJD2</i>	Sigma	For: ATCGGGAGGATCCTGTTGAC Rev: GAGTAGGTGATGAAGCAAAGACTG
<i>PDX1</i>	Sigma	For: TGCTAGAGCTGGAGAAGGAG Rev: TTGATGTGTCTCTCGGTCAA
<i>CACNA1G</i>	Sigma	For: GCTTCGGAACCGATGCTTC Rev: TCCTCGTTCTCTGTCTGGTAAT
<i>CACNA1H</i>	Sigma	For: TCTTCTTCTGCCTCGGTCA Rev: CACGCAGTTGAGCATGATT
<i>CACNA1I</i>	Sigma	For: GGAGCTGATCCTCATGTCCC Rev: CACGGGTTGCACACCATCT
<i>CACNA1A</i>	Sigma	For: GATTTTAGCCACCATCATAGCGA Rev: CCAGCCGTTCCAGACATCGG
<i>CACNA1C</i>	Sigma	For: TCCAGAAGATGATTCCAACG Rev: ATTGGGGTGAAAGAGGAGTC
<i>CACNA1D</i>	Sigma	For: CGCGAACGAGGCAAACATATG Rev: TTGGAGCTATTCGGCTGAGAA
<i>CACNA1A</i>	Sigma	For: GATTTTAGCCACCATCATAGCGA Rev: CCAGCCGTTCCAGACATCGG
<i>SCN1B</i>	Sigma	For: GTCTACCGCTGCTCTTCTTC Rev: TGGATGCCATGTCTCTGTTG
<i>SCN3A</i>	Sigma	For: TTCACTAATGCCTGGTGCTG Rev: CCGAGTTCTGAGTAGCCAAGAG
<i>SCN3B</i>	Sigma	For: ATTGTTTCCCCTGGCTTCTC Rev: AGGGCACTTCCACACACAC
<i>SCN8A</i>	Sigma	For: AGCACCATCCTATGACACCAC Rev: TGGCTATGAGCTTCAGGAAC
<i>SCN9A</i>	Sigma	For: TCATCTTTGGGTCATTCTTCAC Rev: ACCCCAGCTTTTTTCATTGC
TaqMan™ probes		
<i>Gapdh</i>	Fisher Scientific	Mm99999915_g1
<i>Gjd2</i>	Fisher Scientific	Mm00439121_m1
<i>PPIA</i>	Fisher Scientific	Hs03045993_gH
<i>MAFA</i>	Fisher Scientific	Hs04419862_g1
<i>NEUROG3</i>	Fisher Scientific	Hs00360700_g1

156

157 **Supplementary Table 2:** Primer sequences and probe IDs.